Antiulcer activity of levcromakalim and nicorandil in albino rats: A comparative study

Polish Journal of Pharmacology

Volumn 55, Issue 1, 2003, Pages 91-95

  Bose, Manoj ^a   Motghare, Vijay M ^a   Dakhale, Ganesh N ^a   Turankar, Avinash V ^a  

^a GOVERNMENT MEDICAL COLLEGE   (India)

Author keywords

Antiulcer activity; Levcromakalim; Nicorandil; Potassium channel openers

Indexed keywords

ACETYLSALICYLIC ACID; ANTIULCER AGENT; CIMETIDINE; LEMAKALIM; NICORANDIL; POTASSIUM CHANNEL STIMULATING AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DISEASE MODEL; DOSE RESPONSE; DRUG ACTIVITY; DRUG EFFECT; DRUG MECHANISM; FEMALE; IMMOBILIZATION STRESS; MALE; NONHUMAN; PYLORUS LIGATION; RAT; RAT STRAIN; STOMACH BLOOD FLOW; STOMACH JUICE; STOMACH MUCOSA; STOMACH PH; STOMACH SECRETION; STOMACH ULCER; TREATMENT OUTCOME; WATER IMMERSION;

ANIMALS; ANTI-ULCER AGENTS; CROMAKALIM; FEMALE; MALE; NICORANDIL; RATS; RATS, WISTAR; STOMACH ULCER;

EID: 0037251010     PISSN: 12306002     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. 2 receptor activation in stress ulceration in rats. Eur. J. Pharmacol., 1979, 55, 23-33.
2. Cook N.S., Hof R.P.: Cardiovascular effect of apamin and BRL 34915 in rats and rabbits. Brit. J. Pharmacol., 1988, 93, 121-131.
3. Davenport H.W.: Salicylate damage to the gastric mucosal barrier. N. Engl. J. Med., 1967, 276, 1307-1312.
4. Dayal Y., DeLellis R.A.: Peptic ulcer. In: Robbins Pathological Basis of Disease. Eds. Cotran R., Kumar V., 4th edn., W.B. Saunders Co., 1989, 848-853.
5. Desai J.K., Goyal R.K., Parmar N.S.: Pathogenesis of peptic ulcer disease and current trends in therapy. Indian J. Physiol. Pharmacol., 1997, 41, 3-15.
6. Doi K., Nagao T., Kawa K., Iida M., Fujishima M.: Calcitonin gene related peptide affords gastric mucosal protection by activating potassium channel in Wistar rats. Gastroenterology, 1998, 114, 71-76.
7. Goswani S., Jain S., Santani D.: Antiulcer activity of cromakalim against experimentally induced gastric and duodenal ulcers in rats and guinea pigs. J. Pharm. Pharmacol., 1997, 49, 195-199.
8. Hamilton T.C., Weir S.W., Weston A.H.: Comparison of the effects of BRL 34915 and verapamil on electrical and mechanical activity in rat portal vein. Brit. J. Pharmacol., 1986, 88, 103-111.
9. Henke P.G.: The telencephalic limbic system and experimental gastric pathology: a review. Neurosci. Biobehav. Rev., 1982, 6, 381-390.
10. Kitagawa H., Fujiwara M., Osumi Y.: Effect of water immersion stress on gastric secretion and mucosal blood flow in rats. Gastroenterology, 1979, 77, 298-302.
11. Lawrence S.F., Walter L.P.: Peptic ulcer and related diseases. In: Harrison's Principle of Internal Medicine. Eds. Fauci A.S., Isselbacher K.J., Longo D.L., 14th edn., McGraw Hill, 1998, 284, 1596-1605.
12. Masuda E., Kawano S., Nagano K., Tsuji S., Kamada T.: Endogenous nitric oxide modulates ethanol-induced gastric mucosal injury in rats. Gastroenterology, 1995, 108, 58-64.
13. Parmar N.S., Desai J.K.: A review of the current methodology for the evaluation of gastric and duodenal antiulcer agents. Indian J. Pharmacol., 1993, 25, 120-135.
14. Rosa S.D., Vishwanath G.D.: Gastric cytoprotection. Indian J. Physiol. Pharmacol., 1991, 35, 88-98.
15. Sakai K., Saito K.: Nicorandil, its dinitrated metabolite, SG-86 and naturally occurring vasodilators synergistically interact on adenosine-induced vasodepression in rats: special reference to adrenomedullin. Fundam. Clin. Pharmacol., 1999, 13, 27-33.
16. Smirnov I.V., Oslopob V.N., Mendelevich V.D.: Epidemiological aspects of combined arterial hypertention and peptic ulcer. Terapevt. Arkh., 1990, 62, 48-50.
17. Sternini C., Reeve J.R., Brecha N.: Distribution and characterization of calcitonin gene related peptide immunoreactivity in the digestive system of normal and capsaicin-treated rats. Gastroenterology, 1987, 93, 852-862.